Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
Language English Country Netherlands Media print-electronic
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
PubMed
29153614
DOI
10.1016/j.jneuroim.2017.10.009
PII: S0165-5728(17)30259-X
Knihovny.cz E-resources
- Keywords
- Alemtuzumab, CD4+ lymphocytes, Immune reconstitution, Multiple sclerosis, Treatment response,
- MeSH
- Alemtuzumab therapeutic use MeSH
- CD4-Positive T-Lymphocytes drug effects pathology MeSH
- Adult MeSH
- Humans MeSH
- Antineoplastic Agents, Immunological therapeutic use MeSH
- Multiple Sclerosis drug therapy MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Alemtuzumab MeSH
- Antineoplastic Agents, Immunological MeSH
Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4+ cell percentage was not or just mildly affected and was slightly below the lowest normal limit already before alemtuzumab. These cases anticipate further studies aimed to investigate whether the evaluation of the CD4+ cell percentage could represent a helpful tool to address the individual clinical response to alemtuzumab.
References provided by Crossref.org
